Podcast

Dr Javed Butler: Up-titrating Vericiguat

Dr. Javed Butler explains optimization of the use of vericiguat in heart failure management while addressing concerns like hypotension and medication tolerance. He emphasizes the importance of individualized care. Clinical trials like Victoria demonstrated excellent tolerance, with most patients achieving the target dose of 10 mg. Dr. Butler suggests staggering medications, adjusting diuretics, and eliminating unnecessary drugs to minimize side effects like low blood pressure. He stresses that even lower doses of vericiguat are better than none, advocating gradual titration and close monitoring for effective therapy.

Our speakers
  • MD, MPH, MBA, Baylor Scott and White Health.

    Dr. Javed Butler is a prominent figure in cardiovascular medicine, especially known for his work on heart failure. Based in Dallas, Texas, he holds leadership positions at Baylor Scott & White, including the Maxwell A. and Gayle H. Clampitt Endowed Chair, president, and chief research executive at the Research Institute, and senior vice president at the Health system. His expertise is recognized by his fellowships in several prestigious organizations, such as the Heart Failure Society of America, the European Society of Cardiology, the American College of Cardiology, and the American Heart Association.

Related content